You are here

  • Home
  • Archive
  • Volume 69, Issue 9
  • Hormonal replacement therapy may reduce the risk for RA in women with early arthritis who carry HLA-DRB1 *01 and/or *04 alleles by protecting against the production of anti-CCP: results from the ESPOIR cohort

Article Text

Article menu
Download PDFPDF
Clinical and epidemiological research
Concise report
Hormonal replacement therapy may reduce the risk for RA in women with early arthritis who carry HLA-DRB1 *01 and/or *04 alleles by protecting against the production of anti-CCP: results from the ESPOIR cohort
  1. Carine Salliot1,2,
  2. Claire Bombardier2,3,
  3. Alain Saraux4,
  4. Bernard Combe5,
  5. Maxime Dougados1
  1. 1Paris Descartes University, Medicine Faculty UPRES-EA 4058 APHP, Rheumatology B Department, Cochin Hospital, Paris, France
  2. 2Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Canada
  3. 3Department of Medicine at University of Toronto, Canada
  4. 4Department of Rheumatology, University Hospital, Brest, France
  5. 5Department of Rheumatology, Lapeyronnie University Hospital, Montpellier, France
  1. Correspondence to Dr Carine Salliot, Paris Descartes University, Medicine Faculty UPRES-EA 4058 APHP, Hôpital Cochin, Service de Rhumatologie B, rue du faubourg Saint-Jacques, 75014 Paris, France; carinesalliot{at}cch.aphp.fr

Abstract

Objective To assess the effect of reproductive factors, especially hormone replacement therapy (HRT) and its interaction with HLA-DRB1 *01 and/or *04 alleles on the diagnosis of rheumatoid arthritis (RA) and the presence of anti-cyclic citrullinated peptide (CCP) antibodies in women included in the ESPOIR cohort (early arthritis cohort).

Methods 568 patients were included in the analyses, which were performed using logistic regression.

Results HRT reduced the risk of RA due to the HLA-DRB1 *01 and/or *04 alleles from OR 1.88 (95% CI 1.32 to 2.68, p<0.000) for HLA-DRB1 *01 and/or *04 alleles alone to OR 1.07 (95% CI 0.51 to 2.26, p=0.85) in women with HLA-DRB1 *01 and/or *04 alleles who received HRT. One explanation might be the protective effect of HRT on the presence of anti-CCP antibodies (OR 0.43, 95% CI 0.24 to 0.77, p<0.006). Other reproductive factors such as the number of pregnancies, menopause and age at menopause, age at menarche and a history of pregnancy with poor outcome were not associated with the diagnosis of RA and the presence of anti-CCP antibodies.

Conclusion HRT may reduce the risk of RA due to HLA-DRB1 *01 and/or *04 alleles by protecting against the production of anti-CCP antibodies.

https://doi.org/10.1136/ard.2009.111179

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Funding An unrestricted grant from Merck Sharp and Dohme (MSD) was allocated for the first 5 years. Two additional grants from INSERM were obtained to support part of the biological database. The French Society of Rheumatology, Abbott and Wyeth also supported the ESPOIR cohort study.

    • Patient consent Obtained.

    • Ethics approval This study was conducted with the approval of the Lapeyronnie University Hospital, Montpellier, France.

    • Provenance and peer review Not commissioned; externally peer reviewed.